Cyberonics Announces First Enrolled Patient in New Epilepsy Study

Cyberonics announced that the first patient was enrolled in its E20 Phase IV epilepsy study of patients with less chronic and less resistant medically refractory partial onset seizures. The E20 study is a Phase IV, postapproval, multicenter, open-label, parallel-group, active treatment control trial comparing patients who have partial seizures refractory to at least two, but not more than five, anticonvulsant medications treated with adjunctive VNS Therapy plus standard of care treatment-as-usual to patients treated with only standard of care treatment-as-usual (no VNS) over a one-year period.

ArriveNet (http://press.arrivenet.com/bus/article.php/591760.html)